在感染人类免疫缺陷病毒的患者中，乙型肝炎或丙型肝炎病毒感染是启动含蛋白酶抑制剂的抗逆转录病毒治疗方案后发生严重肝细胞溶解的一个危险因素。APROCO研究组。
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.
作者信息
Savès M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Rivière C, Chêne G, Leport C
机构信息
INSERM Unité 330, 33076 Bordeaux Cedex, France.
出版信息
Antimicrob Agents Chemother. 2000 Dec;44(12):3451-5. doi: 10.1128/AAC.44.12.3451-3455.2000.
Abstract
In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level >/= 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7. 95; P < 10(-3)) or hepatitis B virus surface antigen (HR, 6.67; P < 10(-3)) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.
摘要
在1047例开始使用蛋白酶抑制剂（PI）治疗的1型人类免疫缺陷病毒感染患者队列中，经过平均5个月的随访，严重肝细胞溶解（丙氨酸转氨酶浓度高于正常水平上限五倍或更多，即≥5N）的发生率为5%患者年。仅丙型肝炎病毒抗体阳性（风险比[HR]，7.95；P<10⁻³）或乙型肝炎病毒表面抗原阳性（HR，6.67；P<10⁻³）与严重细胞溶解相关。在患者开始使用PI之前，评估肝酶水平和病毒合并感染是必要的。
相似文献
1
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.
Antimicrob Agents Chemother. 2000 Dec;44(12):3451-5. doi: 10.1128/AAC.44.12.3451-3455.2000.
2
Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function.
J Postgrad Med. 2006 Apr-Jun;52(2):92-6.
3
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
AIDS. 1998 Dec 3;12(17):2289-93. doi: 10.1097/00002030-199817000-00010.
4
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.
Arch Intern Med. 2002 Oct 14;162(18):2125-32. doi: 10.1001/archinte.162.18.2125.
5
Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
AIDS. 1999 Dec 3;13(17):F115-21. doi: 10.1097/00002030-199912030-00002.
6
The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte levels in the highly HIV infected population of North-Central Nigeria.
Mem Inst Oswaldo Cruz. 2007 Jun;102(4):535-7. doi: 10.1590/s0074-02762007005000025.
7
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
Clin Infect Dis. 2010 Feb 15;50(4):502-11. doi: 10.1086/649922.
8
Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.
Arch Virol. 2015 Apr;160(4):929-36. doi: 10.1007/s00705-014-2311-0. Epub 2015 Jan 24.
9
Interference of replication between hepatitis B and C viruses in patients infected with HIV.
J Med Virol. 2011 Jul;83(7):1159-64. doi: 10.1002/jmv.22102.
10
Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus, Treponema pallidum, and co-infections among blood donors in Kyrgyzstan: a retrospective analysis (2013-2015).
Infect Dis Poverty. 2017 Feb 21;6(1):45. doi: 10.1186/s40249-017-0255-9.
引用本文的文献
1
Mechanistic insights into antiretroviral drug-induced liver injury.
Pharmacol Res Perspect. 2020 Aug;8(4):e00598. doi: 10.1002/prp2.598.
2
Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals.
PLoS One. 2019 Dec 17;14(12):e0226573. doi: 10.1371/journal.pone.0226573. eCollection 2019.
3
Hepatic histomorphological and biochemical changes following highly active antiretroviral therapy in an experimental animal model: Does exacerbate hepatic injury?
Toxicol Rep. 2016 Jan 6;3:114-122. doi: 10.1016/j.toxrep.2015.12.013. eCollection 2016.
4
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.
Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1172-1181. doi: 10.1002/pds.4258. Epub 2017 Jul 19.
5
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.
Hepat Mon. 2014 Aug 5;14(8):e15426. doi: 10.5812/hepatmon.15426. eCollection 2014 Aug.
6
Antiviral and immune stimulant activities of glycyrrhizin against duck hepatitis virus.
Afr J Tradit Complement Altern Med. 2012 Apr 2;9(3):389-95. doi: 10.4314/ajtcam.v9i3.14. eCollection 2012.
7
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature.
BMC Infect Dis. 2012 Oct 14;12:257. doi: 10.1186/1471-2334-12-257.
8
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24.
9
Epidemiology of idiosyncratic drug-induced liver injury.
Semin Liver Dis. 2009 Nov;29(4):337-47. doi: 10.1055/s-0029-1240002. Epub 2009 Oct 13.
10
Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone.
Diabetologia. 2008 Nov;51(11):2108-16. doi: 10.1007/s00125-008-1133-6. Epub 2008 Aug 23.
本文引用的文献
1
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.
Clin Infect Dis. 2000 Apr;30 Suppl 1:S29-65. doi: 10.1086/313848.
2
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
AIDS. 1998 Dec 3;12(17):2289-93. doi: 10.1097/00002030-199817000-00010.
3
Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.
Clin Infect Dis. 1998 Nov;27(5):1255-8. doi: 10.1086/514987.
4
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
N Engl J Med. 1998 Oct 29;339(18):1269-76. doi: 10.1056/NEJM199810293391802.
5
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
N Engl J Med. 1998 Oct 29;339(18):1261-8. doi: 10.1056/NEJM199810293391801.
6
Acute hepatitis in HIV-infected patients during ritonavir treatment.
AIDS. 1998 Sep 10;12(13):1722-4.
7
Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects.
Clin Infect Dis. 1998 May;26(5):1104-6. doi: 10.1086/520281.
8
Is the combination of hepatitis and indinavir potentially dangerous?
AIDS. 1998 Mar 5;12(4):441-2.
9
Indinavir-associated hepatitis in patients with advanced HIV infection.
Int J STD AIDS. 1998 Jan;9(1):53. doi: 10.1258/0956462981920883.
10
Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.
J Infect Dis. 1998 Mar;177(3):783-5. doi: 10.1086/517808.
Zotero 插件